Merck's Q3 2025 Earnings Surpass Expectations with Oncology Sales Growth
AI Summary1 min read
TL;DR
Merck's Q3 2025 earnings beat estimates with $17.3B revenue and $2.58 EPS, driven by strong oncology sales including KEYTRUDA at $8.1B, though vaccines like GARDASIL declined 25%.
Tags
MerckQ3 2025 earningsOncology salesKEYTRUDAGARDASIL
Merck & Co. Inc. (NYSE:MRK) reported Q3 2025 earnings with revenue of $17.3 billion, exceeding analyst estimates of $16.98 billion. EPS was $2.58, surpassing projections of $2.35. Oncology division led growth, with KEYTRUDA sales of $8.1 billion. However, vaccines division faced challenges, with GARDASIL sales falling 25% to $1.7 billion.
